These include stomach upset, GI bleeds, kidney or liver problems, reducing the bodys ability to heal, and increasing the risk of high blood pressure, heart attack, or stroke
Systemic corticosteroids are prescribed for severe reactions and tapered over 23 weeks to prevent a recurrence of the rash
Gao M, Yi J, Zhu J, Minikes AM, Monian P, Thompson CB, et al
The success of GLP-1 therapies has driven: Increased research investments Expansion of manufacturing capacity Development of new formulations Greater focus on metabolic disease management India is now emerging as an important market for these innovative therapies
That gap is the largest reported in any Phase 3 obesity trial